MILWAUKEE, April 17, 2023 /PRNewswire/ -- Ademi LLP is investigating Prometheus (NASDAQ: RXDX) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck.

AdemiLogo (PRNewsfoto/Ademi LLP)

Click here to learn how to join the action https://www.ademilaw.com/case/prometheus-biosciences-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

Ademi LLP alleges Prometheus' financial outlook and prospects are excellent and yet Prometheus' shareholders are expected to receive only $200.00 per share in cash for a total equity value of approximately $10.8 billion. The transaction agreement unreasonably limits competing bids for Prometheus by imposing a significant penalty if Prometheus accepts a superior bid. Prometheus insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Prometheus' board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Prometheus.

If you own Prometheus common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/prometheus-biosciences-inc. 

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-prometheus-biosciences-inc-has-obtained-a-fair-price-in-its-transaction-with-merck-301798587.html

SOURCE Ademi LLP